CD5

Chr 11

CD5 molecule

Also known as: LEU1, T1

NCBI Gene: 921ENSG00000110448UniProt: P06127

This gene encodes a member of the scavenger receptor cysteine-rich (SRCR) superfamily. Members of this family are secreted or membrane-anchored proteins mainly found in cells associated with the immune system. This protein is a type-I transmembrane glycoprotein found on the surface of thymocytes, T lymphocytes and a subset of B lymphocytes. The encoded protein contains three SRCR domains and may act as a receptor to regulate T-cell proliferation. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Oct 2016]

75
ClinVar variants
10
Pathogenic / LP
0.00
pLI score
5
Active trials
Clinical Summary— CD5
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
10 Pathogenic / Likely Pathogenic· 59 VUS of 75 total submissions
💊
Clinical Trials
5 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.03LOEUF
pLI 0.000
Z-score 1.44
OE 0.70 (0.49–1.03)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.96Z-score
OE missense 0.84 (0.76–0.94)
241 obs / 286.8 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.70 (0.49–1.03)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.84 (0.76–0.94)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.96
0≤1.21.6
LoF obs/exp: 19 / 27.1Missense obs/exp: 241 / 286.8Syn Z: 0.32

ClinVar Variant Classifications

75 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic6
Likely Pathogenic4
VUS59
Likely Benign4
Benign2
6
Pathogenic
4
Likely Pathogenic
59
VUS
4
Likely Benign
2
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
6
0
6
Likely Pathogenic
0
0
4
0
4
VUS
0
56
3
0
59
Likely Benign
0
3
0
1
4
Benign
0
2
0
0
2
Total06113175

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CD5 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
📖
GeneReview available — CD5
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
CD5 deletion enhances the antitumor activity of adoptive T cell therapies.
Patel RP et al.·Sci Immunol
2024
mRNA-Engineered CD5-CAR-γδT(CD5-) Cells for the Immunotherapy of T-Cell Acute Lymphoblastic Leukemia.
Zhu Z et al.·Adv Sci (Weinh)
2024
The CD5+ B-cell.
Dono M et al.·Int J Biochem Cell Biol
2004Review
Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.
Nato Y et al.·Hematol Oncol
2025
Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
Isaac KM et al.·Curr Oncol Rep
2021Review
Recent advances in CD5(+) diffuse large B-cell lymphoma.
Yue N et al.·Ann Hematol
2024Review
How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.
Cabeçadas J et al.·Curr Oncol
2021Review
Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM et al.·J Immunother Cancer
2024
Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis.
Pape K et al.·Brain
2026
CD5 and p53 immunohistochemistry: valuable prediction method in molecular typing of CD5-positive diffuse large B-cell lymphoma.
Wang H et al.·BMC Cancer
2025
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
T-cell Acute Lymphoblastic LymphomaT-non-Hodgkin LymphomaT-cell Acute Lymphoblastic Leukemia

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

RECRUITING
NCT03081910Phase PHASE1Baylor College of MedicineStarted 2017-11-01
Autologous CD5.CAR/28zeta CAR T cellsAllogeneic CD5.CAR/28zeta CAR T cells
Diffuse Large B Cell Lymphoma (DLBCL)

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

RECRUITING
NCT06647940Phase PHASE2Sun Yat-sen UniversityStarted 2024-11-01
Orelabrutinib Oral TabletR-CHOP Protocol
Non Hodgkin LymphomaFollicular LymphomaMarginal Zone Lymphoma

BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.

ACTIVE NOT RECRUITING
NCT06424379Hospices Civils de LyonStarted 2024-01-01
Histopathological analysisMolecular analysis
Prolymphocytic LeukemiaT-cell Leukemia

Observatory of Prolymphocytic Leukemia T

RECRUITING
NCT04411043French Innovative Leukemia OrganisationStarted 2020-07-01
Molecular caracterization
Diffuse Large B Cell Lymphoma

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

RECRUITING
NCT04300101Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSStarted 2020-05-14
Prospective cohortRetrospective cohort

External Resources

Links to major genomics databases and tools